Company: CYTK
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001193125-25-039426
Chunk: 45

Company: CYTOKINETICS INC
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 45
---
. |

| Common stock to be outstanding after this offering | Up to 128,879,220 shares of common stock, assuming sales of 10,670,081 shares of our common stock in this offering at an assumed offering price of $46.86 per share, which was the last reported sale price of our common stock on The 
 Nasdaq Global Select Market on February 26, 2025. The actual number of shares issued will vary depending on the sales prices at which our common stock is sold under this offering.                                                    |

| Plan of Distribution | “At the market offering” that may be made from time to time through or to Jefferies, as sales agent. See “Plan of Distribution” on page S-11. |

| Use of Proceeds | We intend to use the net proceeds from this offering, if any, for working capital and general corporate purposes. We may also use a portion of the net proceeds to in-license, acquire, or invest in  
 additional businesses, technologies, products, or assets, though we currently have no specific agreements, commitments or understanding with respect to any in-licensing or acquisitions. See “Use of 
 Proceeds” on page S-8.                                                                                                                                                                                |

| Risk Factors | Investment in our common stock involves a high degree of risk and uncertainty. You should read the “Risk Factors,” beginning on page S-4 of this prospectus supplement, page 5 of the accompanying                        
 prospectus and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock. |

| Nasdaq Global Select Market symbol | “CYTK” |

The number of our shares of common stock to be outstanding after this offering is based on an aggregate of 118,209,139 shares of our common stock outstanding as of December 31, 2024, and excludes the following:

| • |     | 10,419,523 shares of common stock underlying options outstanding at a weighted average exercise price of $31.84 
 per share;                                                                                                      |

| • |     | 1,865,058 shares of common stock underlying restricted stock units and performance stock units outstanding; |

| • |     | 12,575,140 shares reserved for future issuance pursuant to the conversion of our outstanding convertible senior 
 notes; and                                                                                                      |

| • |     | 5,326,506 shares of common stock available for future grant of equity awards under our equity incentive plans